Anti-MYH11 monoclonal antibody

Pre-made anti-MYH11 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to MYH11/MYH11 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2614-Ab-1/ GM-Tg-hg-IP2614-Ab-2Anti-Human MYH11 monoclonal antibodyHuman
GM-Tg-rg-IP2614-Ab-1/ GM-Tg-rg-IP2614-Ab-2Anti-Rat MYH11 monoclonal antibodyRat
GM-Tg-mg-IP2614-Ab-1/ GM-Tg-mg-IP2614-Ab-2Anti-Mouse MYH11 monoclonal antibodyMouse
GM-Tg-cynog-IP2614-Ab-1/ GM-Tg-cynog-IP2614-Ab-2Anti-Cynomolgus/ Rhesus macaque MYH11 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2614-Ab-1/ GM-Tg-felg-IP2614-Ab-2Anti-Feline MYH11 monoclonal antibodyFeline
GM-Tg-cang-IP2614-Ab-1/ GM-Tg-cang-IP2614-Ab-2Anti-Canine MYH11 monoclonal antibodyCanine
GM-Tg-bovg-IP2614-Ab-1/ GM-Tg-bovg-IP2614-Ab-2Anti-Bovine MYH11 monoclonal antibodyBovine
GM-Tg-equg-IP2614-Ab-1/ GM-Tg-equg-IP2614-Ab-2Anti-Equine MYH11 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2614-Ab-1/ GM-Tg-hg-IP2614-Ab-2; GM-Tg-rg-IP2614-Ab-1/ GM-Tg-rg-IP2614-Ab-2;
GM-Tg-mg-IP2614-Ab-1/ GM-Tg-mg-IP2614-Ab-2; GM-Tg-cynog-IP2614-Ab-1/ GM-Tg-cynog-IP2614-Ab-2;
GM-Tg-felg-IP2614-Ab-1/ GM-Tg-felg-IP2614-Ab-2; GM-Tg-cang-IP2614-Ab-1/ GM-Tg-cang-IP2614-Ab-2;
GM-Tg-bovg-IP2614-Ab-1/ GM-Tg-bovg-IP2614-Ab-2; GM-Tg-equg-IP2614-Ab-1/ GM-Tg-equg-IP2614-Ab-2
Products NameAnti-MYH11 monoclonal antibody
Formatmab
Target NameMYH11
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-MYH11 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2614-Ag-1Recombinant multi-species MYH11/ AAT4/ FAA4 protein


    Target information

    Target IDGM-IP2614
    Target NameMYH11
    Gene ID4629,17880,24582,713882,479836,101097693,530050,100050346
    Gene Symbol and SynonymsAAT4,FAA4,MYH11,SM1,SM2,SMHC,SMMHC,SMMS-1,VSCM2
    Uniprot AccessionP35749,Q63862
    Uniprot Entry NameMYH11_HUMAN,MYH11_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseCancer
    Gene EnsemblENSG00000133392
    Target ClassificationTumor-associated antigen (TAA)

    The target: MYH11, gene name: MYH11, also named as AAT4, FAA4, SMHC, SMMHC. The protein encoded by this gene is a smooth muscle myosin belonging to the myosin heavy chain family. The gene product is a subunit of a hexameric protein that consists of two heavy chain subunits and two pairs of non-identical light chain subunits. It functions as a major contractile protein, converting chemical energy into mechanical energy through the hydrolysis of ATP. A chromosomal rearrangement involving this gene is associated with acute myeloid leukemia of the M4Eo subtype. Mutations in this gene are associated with visceral myopathy, megacystis-microcolon-intestinal hypoperistalsis syndrome 2, and familial thoracic aortic aneurysm 4. [provided by RefSeq, May 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.